Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/31/2005WO2004103356A3 Treatment of emotional dysregulation
03/31/2005WO2004103299A8 Compositions and methods for the treatment of cns injuries
03/31/2005WO2004098617A3 Controlled release composition containing a strontium salt
03/31/2005WO2004098591A3 Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
03/31/2005WO2004098538A3 Nitrosated and nitrosylated compounds, compositions and methods of use
03/31/2005WO2004098496A3 Compounds for the treatment of metabolic disorders
03/31/2005WO2004096276A9 Sugar intake-ability enhancer
03/31/2005WO2004096154A3 Methods for treating degenerative diseases/injuries
03/31/2005WO2004093722A3 Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
03/31/2005WO2004092172A3 Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
03/31/2005WO2004092171A3 Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists
03/31/2005WO2004092170A3 Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
03/31/2005WO2004091578A3 Novel encochleation methods, cochleates and methods of use
03/31/2005WO2004091553A3 Film forming polymers, methods of use, and devices and applications thereof
03/31/2005WO2004089307A3 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
03/31/2005WO2004087158A3 Muscarinic m1 receptor agonists for pain management
03/31/2005WO2004087076A3 Methods for inhibiting adipogenesis and for treating type 2 diabetes
03/31/2005WO2004084824A3 Biaryl substituted 6-membered heterocyles as sodium channel blockers
03/31/2005WO2004083155A3 Nucleotide lipid ester derivatives
03/31/2005WO2004080383A3 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
03/31/2005WO2004075856A3 Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
03/31/2005WO2004073606A3 Sulfonamide derivatives as ppar modulators
03/31/2005WO2004069187A3 Drug formulation and delivery using crystalline methylated cyclodextrins
03/31/2005WO2004064748A3 Compositions and methods for treatment of ovarian cancer
03/31/2005WO2004064742A3 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms
03/31/2005WO2004064734A3 Combination therapies for the treatment of cancer
03/31/2005WO2004060320A3 Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
03/31/2005WO2004058160A3 Compounds for the normalization of the sleep/wake cycle
03/31/2005WO2004054509A3 Tetracyclines as anti-fungal agents for treatment of ringworm
03/31/2005WO2004052899A3 Process for the production of 2'-branched nucleosides
03/31/2005WO2004052227A3 Superoxide dismutase mimics for the treatment of ocular disorders and diseases
03/31/2005WO2004050040A3 Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
03/31/2005WO2004039247A3 Compositions and methods for pain reduction
03/31/2005WO2004032900A8 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
03/31/2005WO2004032876A3 Deguelin as a chemopreventive agent for lung cancer
03/31/2005WO2004009026A8 Cholinergic therapy for individuals with learning disabilities
03/31/2005WO2004006959A8 Liquid dosage compositions of stable nanoparticulate active agents
03/31/2005WO2003099215A3 Antisense modulation of glucocorticoid receptor expression
03/31/2005WO2003096877A3 Prevention and treatment of streptococcal and staphylococcal infection
03/31/2005WO2003091243A8 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
03/31/2005WO2003087769A3 Method for identifying modulators of ion channels
03/31/2005WO2003079992A3 Pulmonary delivery for levodopa
03/31/2005WO2003073987A3 Compounds that modulate the activity of ptp-1b and tc-ptp
03/31/2005WO2003038060A3 Small molecule inhibitors targeted at bcl-2
03/31/2005WO2002099054A3 Hccss as modifiers of the p53 pathway and methods of use
03/31/2005WO2002067968A9 14-3-3 binding molecules as sensitizers for anticancer therapies
03/31/2005WO2002042319A9 2-substituted estrogens as antiangiogenic agents
03/31/2005US20050071894 Nonhuman model animal lacking the ability to control lymphocyte migration
03/31/2005US20050070877 Therapy for mucous membrane secretions; respiratory system disorders; ostitis; cystic fibrosis; using interstitial compounds
03/31/2005US20050070721 PH-sensitive polymeric micelles for drug delivery
03/31/2005US20050070720 11-Beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
03/31/2005US20050070719 Central nervous system disorders; antidiabetic agents; antiinflammatory agents; antiarthritic agents;obesity; osteoporosis ; anticancer agents
03/31/2005US20050070713 Neurokinin antagonist; therapy for central nervous system disorders; psychological disorders; Parkinson's and Huntington's disease
03/31/2005US20050070712 Pyrimidine derivatives as ghrelin receptor modulators
03/31/2005US20050070706 Antidiabetic agents; obesity; controlling appetite
03/31/2005US20050070670 Novel adjuvants and copolymer compositions
03/31/2005US20050070613 deoxygenating aqueous solutions of catecholamines using inert gases, buffering, sterilization and storing in bottles; stabilization
03/31/2005US20050070612 Monitoring cell proliferation of prostate cancer cells; incubation with quercetin; monitoring adjustment of gene expression
03/31/2005US20050070611 Solubilized CoQ-10
03/31/2005US20050070610 Dermal compositions containing coenzyme q as the active ingredient
03/31/2005US20050070609 Cyclopentyl modulators of chemokine receptor activity
03/31/2005US20050070608 Pharmaceutical compositions and method of using levodopa and carbidopa
03/31/2005US20050070607 Prevent liver damage; respiratory system disorders; cardiovascular disorders; endocrine disorders; infections; monitoring concentration of glutathion in blood
03/31/2005US20050070606 Pharmaceutical agent for mitochondrial disorders
03/31/2005US20050070605 Reacting an organophosphouus compound with metallized alkane; forming atorvastatin, lorastatin, pitavastatin, fluvastatin
03/31/2005US20050070604 Vaginal cleanser; inhibit production of exotoxins from grampositive bacteria
03/31/2005US20050070603 Irritable bowel syndrome; using glyceride of glycerin and fatty acid
03/31/2005US20050070602 Method of modulating immune response by administration of immuno-activation agent
03/31/2005US20050070601 Stimulating metabolism; decrease appetite for food; adjust energy ; side effect reduction
03/31/2005US20050070600 Tuberculosis therapy; mixture of cantharidic anhydride in vegetable oil; solvent extraction of plant extracts
03/31/2005US20050070599 Crystal forms of 4-[4-(4-fluorophenoxy)benzenesulfonylamino]-tetrahydropyran-4-carboxylic acid hydroxyamide
03/31/2005US20050070596 Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
03/31/2005US20050070595 Complex of trioxane with iron compound
03/31/2005US20050070594 Use of angiotensin II receptor antagonists
03/31/2005US20050070591 Indole derivative
03/31/2005US20050070590 possessing anti-cancer activity, anti-inflammatory activity, anti-obesity activity, and/or hair growth promotion activity
03/31/2005US20050070586 Reacting potassium alcoholates with trityl losartan in methanol, refluxing, distilling out the methanol, crystallization, filtration and vacuum drying; angiotensin II receptor antagonists; hypotensive agents
03/31/2005US20050070585 Serine protease inhibitor; angiogenesis factor; antitumor agents; atherosclerosis; thrombosis; chronic obstructive pulmonary disorders; Alzheimer's disease; anticancer agents; antidiabetic agents; cardiovascular disorders
03/31/2005US20050070584 Substituted aryloximes
03/31/2005US20050070582 For example,1-{[2-(3,5-dimethylphenoxy)-5-nitrophenyl]sulfonyl}-4-ethylpiperazine or 1-{[2-(3,5-dichlorophenoxy)-5-nitrophenyl]sulfonyl}piperazine; for the treatment of asthma, atopic dermatitis, allergic rhinitis and other inflammatory/immunological disorders
03/31/2005US20050070581 such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease
03/31/2005US20050070579 Performing crystallization by using an organic solvent selected from a ketone solvent, a nitrile solvent, and a mixture thereof, or a mixture of organic solvent and water; acetone or acetonitrile can be preferably used as the organic solvent
03/31/2005US20050070578 Using hedgehog antagonist; controlling cell differentiation, cell proliferation
03/31/2005US20050070577 Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
03/31/2005US20050070575 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents
03/31/2005US20050070574 Novel compounds
03/31/2005US20050070573 e.g., 6-chloro-2-methyl-4-(N-(2-(N-(p-methoxyphenylsulfonyl)-N-(2-(2,5-dimethoxy-4-nitroanilinocarbonyl)ethyl)amino)ethyl)amino)quinoline; used to treat inflammatory and immune diseases by binding to CXCR3 receptors.
03/31/2005US20050070572 Sulfone derivatives and their use in the treatment of autoimmune diseases and allergies
03/31/2005US20050070571 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents
03/31/2005US20050070569 Alkyne-aryl phosphodiesterase-4 inhibitors
03/31/2005US20050070568 Therapeutic acridone and acridine compounds
03/31/2005US20050070567 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
03/31/2005US20050070566 Imidazoquinoline derivatives
03/31/2005US20050070565 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
03/31/2005US20050070562 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
03/31/2005US20050070561 For example, 2-(3-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-phenylacetamide; use in the treatment of certain diseases, in particular to proliferative disease such as cancer
03/31/2005US20050070560 Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
03/31/2005US20050070559 Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
03/31/2005US20050070558 For example, [4-(2,4-Dioxo-1,3-dipropyl-2,3,4,5-tetrahydro-1H-pyrrolo[3,2-d]pyrimidin-6-yl)phenoxy]acetic acid; useful in preventing mast cell degranulation and therefore useful in treatment of diseases induced by activation of A2b receptor and mast cell activation such as asthma, allergic reactions
03/31/2005US20050070557 Use of pyrazolo(4,3-d)pyrimidine derivatives; for example, 5-(3-chloro-benzyl)-3-isopropyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one
1 ... 4735 4736 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 ... 7860